在接受抗凝固药物治疗的患者中新发现的大脑微型血流,用于二次中风预防
Tereza Šrámková1, Tomáš Vaňásek2, Martin Šrámek1,3
1Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic.
Medicine
|May 26, 2025
概括
直接口服抗凝剂 (DOAC) 和华法林用于心血管栓塞性中风. 在一年内,新的脑微出血发生在10.1%的患者中,抗凝剂类型之间没有显著差异.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管血栓性缺血性中风患者经常接受像DOAC或华法林这样的抗凝药.
- 脑内出血是抗凝治疗的严重风险.
- 在MRI上,脑微出血 (MBs) 表明出血性中风风险增加.
研究的目的:
- 评估心血管血栓性中风后接受抗凝剂治疗的患者一年内出现新的脑微出血 (MB) 的发生率.
- 为了比较不同抗凝固剂治疗组中新出现的MBs的发生率.
主要方法:
- 79名心血管血栓性中风患者接受抗凝药治疗的前性研究.
- 大脑MRI与敏感度加权成像 (SWI) 在基线和1年后.
- 评估和分类新的MBs (深层,叶片,下垂体).
主要成果:
- 基线MBs在21.5%的患者中存在.
- 在1年的随访期间,10.1%的患者出现了新的脑血管.
- 新的MB主要位于叶片和底部区域.
- 在阿皮克萨班,达比加特兰和华法林组之间没有观察到新的MB发病率的统计学上显著差异.
结论:
- 大约10.1%的接受心血管栓塞性中风抗凝剂治疗的患者在一年内出现了新的脑微型出血.
- 抗凝剂的类型 (DOAC或华法林) 并没有显著影响新的MBs的发生率.
- 进一步的研究可能会探索这种患者群体中新的MBs的风险因素和临床影响.
相关概念视频
Venous Thrombosis III: Interprofessional Care
29
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
29
Anticoagulant Drugs: Low-Molecular-Weight Heparins
934
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
934
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K


